Slovenia's Krka Penetrates U.S. Market with Generic Drugs
Novo Mesto, 10 August - KRKA/USA/GENERIC/DRUGS
Slovenia's pharmaceutical producer Krka will start selling its generic drugs on the U.S. market. U.S. Food and Drug Administration (FDA) inspectors have established that Novo mesto-based Krka meets all standards that are required from those producers of active pharmaceutical substances and end products that would like to sell their products on the American market, according to Krka. Last May, Krka sent to FDA all the documents that a company should produce in order to have a drug registered in the USA. The FDA has thus approved four variants of the Enap tables, developed in Krka's own laboratories.
The rest of this news item is available to subscribers.
The news item consists of 330 characters (without spaces) or 71 words words.
Buy the news item. Price: 2 tokens; on account: 0 tokens.